New Shot-in-Tumor combo aims to shrink melanoma before surgery
NCT ID NCT07230613
First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests whether injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgery can destroy more cancer cells and cause fewer side effects than standard treatment. About 50 adults with stage III melanoma that can be surgically removed will receive the injections. The goal is to see if this approach leads to a complete or major disappearance of tumor cells in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA, STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.